Evidence map›Paper›PMID 41656407›Full record

ArticleAnnals of surgical oncology2026

Percutaneous Biopsy and Recurrence Risk in Stage 1 Renal Cancer: A Propensity Score-Matched Cohort Study.

Jun Hyeok Yoo, Maisy Song, Joung Won Sung, Jungyo Suh, Jung Kwon Kim, Mihyun Kim, Kye Jin Park, Cheryn Song

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jun Hyeok YooDepartment of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Maisy SongDepartment of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Joung Won SungDepartment of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Jungyo SuhDepartment of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Jung Kwon KimDepartment of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Mihyun KimDepartment of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Kye Jin ParkDepartment of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Cheryn SongDepartment of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. cherynsong@amc.seoul.kr.ORCID http://orcid.org/0000-0002-1823-4281

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite the growing incidence of small renal tumors, adoption of percutaneous biopsy remains limited because of concerns about oncologic safety. Lack of robust long-term outcome data further contributes to clinical hesitation regarding routine use. We evaluated the impact of preoperative renal mass biopsy (RMB) on upstaging and recurrence in patients with cT1 renal cell carcinoma (RCC) undergoing definitive surgery.

methodsRetrospective cohort study of 386 consecutive patients who underwent preoperative RMB and 772 propensity score-matched controls who proceeded directly to surgery for cT1 RCC between 2004 and 2022 were compared for recurrence-free survival (RFS) using Kaplan-Meier analysis and Cox proportional hazards regression, and upstaging to perinephric fat invasion by multivariable logistic regression.

resultsAnalytical cohort comprised 882 (76.2%) T1a and 276 (23.8%) T1b patients, with 684 (59.1%) after partial nephrectomy and 474 (40.9%) after radical nephrectomy. During a median follow-up of 58 months (interquartile range 39-77), RFS showed no statistically significant difference (5Y RFS 96.7% vs. 97.8%, p = 0.35). Multivariable analysis confirmed RMB was not associated with recurrence (hazard ratio = 0.71, 95% confidence interval 0.34-1.46, p = 0.35). Independent predictors of recurrence included tumor size, nuclear grade, high nephrometry E score and perinephric fat invasion. Likewise, RMB was not associated with upstaging to perinephric fat invasion (odds ratio 1.64, 95% confidence interval 0.78-3.36, p = 0.182). On multivariable analysis, nephrometry E score was the only significant predictor of perinephric fat invasion.

conclusionPreoperative biopsy in T1 RCC was not associated with adverse oncologic outcomes, affirming its safety and supporting its utility in the management planning of patients with small renal masses.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNeoplasm Recurrence, LocalNephrectomyAgedBiopsyCase-Control StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPrognosisPropensity ScoreRetrospective StudiesCarcinomaRecurrence-free survivalRenal cellRenal mass biopsySmall renal massUpstaging

Identifiers

PMID41656407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.